Zoetis Inc. (ZTS)
USD 150.76
(0.51%)
USD 150.76
(0.51%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.54 Billion USD | 5.74% |
| 2022 | 8.08 Billion USD | 3.91% |
| 2021 | 7.77 Billion USD | 16.49% |
| 2020 | 6.67 Billion USD | 6.63% |
| 2019 | 6.26 Billion USD | 7.47% |
| 2018 | 5.82 Billion USD | 9.76% |
| 2017 | 5.3 Billion USD | 8.57% |
| 2016 | 4.88 Billion USD | 2.58% |
| 2015 | 4.76 Billion USD | -0.42% |
| 2014 | 4.78 Billion USD | 4.91% |
| 2013 | 4.56 Billion USD | 5.19% |
| 2012 | 4.33 Billion USD | 2.43% |
| 2011 | 4.23 Billion USD | 18.17% |
| 2010 | 3.58 Billion USD | 29.78% |
| 2009 | 2.76 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.19 Billion USD | -1.04% |
| 2024 Q3 | 2.38 Billion USD | 1.14% |
| 2024 Q2 | 2.36 Billion USD | 7.81% |
| 2023 Q1 | 2 Billion USD | -1.96% |
| 2023 Q3 | 2.15 Billion USD | -1.33% |
| 2023 Q4 | 2.21 Billion USD | 2.88% |
| 2023 FY | 8.54 Billion USD | 5.74% |
| 2023 Q2 | 2.18 Billion USD | 9.0% |
| 2022 Q3 | 2 Billion USD | -2.44% |
| 2022 Q4 | 2.04 Billion USD | 1.9% |
| 2022 Q1 | 1.98 Billion USD | 0.97% |
| 2022 FY | 8.08 Billion USD | 3.91% |
| 2022 Q2 | 2.05 Billion USD | 3.32% |
| 2021 Q3 | 1.99 Billion USD | 2.16% |
| 2021 Q2 | 1.94 Billion USD | 4.12% |
| 2021 Q1 | 1.87 Billion USD | 3.54% |
| 2021 FY | 7.77 Billion USD | 16.49% |
| 2021 Q4 | 1.96 Billion USD | -1.16% |
| 2020 Q3 | 1.78 Billion USD | 15.37% |
| 2020 FY | 6.67 Billion USD | 6.63% |
| 2020 Q4 | 1.8 Billion USD | 1.18% |
| 2020 Q1 | 1.53 Billion USD | -8.36% |
| 2020 Q2 | 1.54 Billion USD | 0.91% |
| 2019 Q4 | 1.67 Billion USD | 5.68% |
| 2019 Q3 | 1.58 Billion USD | 2.39% |
| 2019 FY | 6.26 Billion USD | 7.47% |
| 2019 Q1 | 1.45 Billion USD | -6.97% |
| 2019 Q2 | 1.54 Billion USD | 6.32% |
| 2018 Q3 | 1.48 Billion USD | 4.59% |
| 2018 Q2 | 1.41 Billion USD | 3.59% |
| 2018 Q1 | 1.36 Billion USD | -6.44% |
| 2018 FY | 5.82 Billion USD | 9.76% |
| 2018 Q4 | 1.56 Billion USD | 5.68% |
| 2017 Q4 | 1.46 Billion USD | 8.39% |
| 2017 Q1 | 1.23 Billion USD | -3.6% |
| 2017 FY | 5.3 Billion USD | 8.57% |
| 2017 Q2 | 1.26 Billion USD | 3.09% |
| 2017 Q3 | 1.34 Billion USD | 6.15% |
| 2016 Q4 | 1.27 Billion USD | 2.9% |
| 2016 FY | 4.88 Billion USD | 2.58% |
| 2016 Q3 | 1.24 Billion USD | 2.73% |
| 2016 Q2 | 1.2 Billion USD | 3.96% |
| 2016 Q1 | 1.16 Billion USD | -8.79% |
| 2015 FY | 4.76 Billion USD | -0.42% |
| 2015 Q4 | 1.27 Billion USD | 4.94% |
| 2015 Q3 | 1.21 Billion USD | 3.32% |
| 2015 Q2 | 1.17 Billion USD | 6.62% |
| 2015 Q1 | 1.1 Billion USD | -16.52% |
| 2014 Q2 | 1.15 Billion USD | 5.56% |
| 2014 Q1 | 1.09 Billion USD | -12.52% |
| 2014 FY | 4.78 Billion USD | 4.91% |
| 2014 Q4 | 1.32 Billion USD | 9.09% |
| 2014 Q3 | 1.21 Billion USD | 4.49% |
| 2013 Q1 | 1.09 Billion USD | -7.31% |
| 2013 Q2 | 1.11 Billion USD | 2.2% |
| 2013 FY | 4.56 Billion USD | 5.19% |
| 2013 Q3 | 1.1 Billion USD | -0.99% |
| 2013 Q4 | 1.25 Billion USD | 13.69% |
| 2012 Q2 | 1.09 Billion USD | 4.49% |
| 2012 Q3 | 1.01 Billion USD | -6.86% |
| 2012 Q4 | 1.17 Billion USD | 15.41% |
| 2012 FY | 4.33 Billion USD | 2.43% |
| 2012 Q1 | 1.04 Billion USD | -7.1% |
| 2011 Q4 | 1.12 Billion USD | 7.44% |
| 2011 Q2 | 1.07 Billion USD | 9.26% |
| 2011 FY | 4.23 Billion USD | 18.17% |
| 2011 Q1 | 983 Million USD | 0.0% |
| 2011 Q3 | 1.04 Billion USD | -2.33% |
| 2010 FY | 3.58 Billion USD | 29.78% |
| 2009 FY | 2.76 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.39 Billion USD | -256.951% |
| Bausch Health Companies Inc. | 8.75 Billion USD | 2.432% |
| Catalent, Inc. | 4.38 Billion USD | -95.024% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -714.257% |
| Elanco Animal Health Incorporated | 4.41 Billion USD | -93.434% |
| Perrigo Company plc | 4.65 Billion USD | -83.521% |
| Teva Pharmaceutical Industries Limited | 15.84 Billion USD | 46.081% |